MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine Nexvet is committed to transforming animal medicine by making remarkable biologic therapies available to veterinarians, pets, and their families. Nexvet aims for global leadership in veterinary biologics – leadership in our science, our people, our products, and in education. They believe their proprietary PETization™ technology can empower veterinarians by providing new tools for managing chronic conditions.

NexVet has been acquired by Zoetis.

Portfolio